ClinicalTrials.gov regulatory outlook
This article was originally published in The Gray Sheet
Executive Summary
National Institutes of Health plans by June 2009 to propose new regulations for registering clinical trials in the ClinicalTrials.gov registry, according to an announcement in the government's fall 2008 Unified Agenda, issued Nov. 24. The regs, which will apply to both device and drug trials, will specify registration procedures and define the information that sponsors or principal investigators must provide. Beverly Lorell, senior medical and policy advisor at the law firm King & Spalding, speculates that the rule will simply formalize the registration policies already in place (1"The Gray Sheet" Sept. 29, 2008, p. 8). In a separate rulemaking, NIH is expected to propose how to handle adverse events in the registry. The FDA Amendments Act requires NIH to finalize an adverse events rule by March 2009; if the rule isn't promulgated by then, the act states, default requirements for adverse event posting will go into effect
You may also be interested in...
Managing The Minefield Of Mandatory Clinical Trial Registration
As key portions of the government's new device clinical trial registry requirements went into effect last week, Medtronic clinical research director Lisa Griffin Vincent offered advice on complying with some of the thornier aspects of the law
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.